Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) said preclinical safety data for its Nu-3 topical gel supported dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers. The company reported Nu-3 was well tolerated in an FDA-required safety study at higher doses, with low systemic exposure and no wound-healing inhibition. Planned gel concentrations are 2%, 5%, and 10%.
How this was made
The 30-second read
Why it matters
The company claims Nu-3 was well-tolerated in an FDA-required safety study at substantially higher doses than planned for Phase 2a, with very low systemic exposure and no inhibition of wound healing. It also selects 2%, 5%, and 10% gel concentrations for the upcoming Phase 2a trial.
Market read
This is a development de-risking update that can improve near-term sentiment and positioning ahead of Phase 2a initiation, but it is not an efficacy or regulatory milestone.
What to watch
Key missing details include the specific safety endpoints, duration of exposure, and any translational biomarkers; investors may discount the news until clinical enrollment and efficacy data are closer.
Background
Lakewood-Amedex is a clinical-stage biotech developing Bisphosphocin-class antimicrobials; Nu-3 is a topical gel for infected diabetic foot ulcers (iDFU).
Ticker impact
Lakewood-Amedex (LABT) reports robust preclinical safety data for Nu-3 and selects 2%, 5%, and 10% gel doses for an upcoming Phase 2a trial.
Near-term sentiment likely positive, but magnitude depends on market expectations for Phase 2a timing and subsequent efficacy readouts.
The release is a primary clinical-development update with specific dose concentrations and a safety claim (well-tolerated, low systemic exposure, no wound-healing inhibition), which can move biotech sentiment ahead of trial initiation.
Market effects
Supports investor appetite for topical antimicrobial programs targeting diabetic foot ulcer infections and antibiotic-resistant strains, but does not change the broader sector fundamentals.
No clear regional market linkage beyond US small/mid-cap biotech sentiment.
Limited global read-through; relevance mainly to wound-infection and topical antimicrobial development pipelines.
Counterpoint
Preclinical safety and dose selection do not guarantee Phase 2a efficacy or tolerability in the target patient population, so the stock reaction may fade without efficacy signals.
Key entities
- companyLakewood-Amedex Biotherapeutics Inc.
NASDAQ-listed clinical-stage biotech advancing Nu-3 gel into Phase 2a after reporting preclinical safety and dose selection.
- product_candidateNu-3 gel
Topical Bisphosphocin compound formulation targeting infected diabetic foot ulcers with low expected systemic side effects.
- clinical_programPhase 2a trial (iDFU)
Upcoming patient study in infected diabetic foot ulcers evaluating 2%, 5%, and 10% Nu-3 gel concentrations.
